Subscribe to our Newsletters !!
Few developments in science and technology have be
In today's fast-paced world of research, accuracy
A new COVID-19 variant, BA.3.2, informally called
The role of AI in research promises to bring new d
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Glythera a UK based Biotechnology Compamy announces the appointment of Dr. Robert Lutz as a Chief Scientific Officer (CSO).
With more than 25 years’ experience, Dr Lutz was previously Vice President of Translation Research and Development at ImmunoGen Inc., where he was responsible for all early-stage ADC development programs and gained further experience in directing the clinical pharmacology, biomarkers, pharmacology and toxicology departments.
The Company CEO Dr Dave Simpson Said,“Robert Lutz’s experience in ADC development will be a great asset as Glythera continues to develop our pipeline of cancer treatments.
With Robert’s appointment as CSO, and the addition of Jon Roffey to our Scientific Advisory Board, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat. ”
For more information: Click here
